Anti-PASD1 [2ALCC136]

Subsequent studies have identified PASD1 expression in myeloma patients (both pre- and post-treatment) and in a broad range of solid tumours, 65/160 samples (41%) from 9 histological types. Interestingly a new immune response to PASD1 was detected in a melanoma patient who exhibited a systemic immune response to palliative radiotherapy with regression of nonirradiated lesions, the abscopal effect.

Contributors

Inventor Institute
Alison Banham ; Karen Pulford University of Oxford
Cat. #: 152546
Tool sub type: Primary antibody
Unit size: 100 ug
Research Fields: Genetics
Application: IHC ; IHC ; IF ; WB
Target: PAS domain-containing protein 1 (PASD1), Per Arnt Sim domain 1
Reactivity: Human
Clone: 2ALCC136
Host: Mouse
Class: Monoclonal
Product description: Cancer testis antigens (CTAs) such as PASD1 represent attractive immunotherapy targets, having normal tissue expression that is testis restricted and commonly widespread expression in tumours. PASD1 was originally identified as a target of anti-tumour immune responses in patients with aggressive diffuse large B-cell lymphoma. Subsequent studies have identified PASD1 expression in myeloma patients (both pre- and post-treatment) and in a broad range of solid tumours, 65/160 samples (41%) from 9 histological types. Interestingly a new immune response to PASD1 was detected in a melanoma patient who exhibited a systemic immune response to palliative radiotherapy with regression of nonirradiated lesions, the abscopal effect. Delivery of immunogenic PASD1 peptides using a DNA vaccine was able to induce immune responses in preclinical models, demonstrating its potential for immunotherapy applications. There is relatively little information regarding the function of many CTAs. However, recently PASD1 has been identified as a novel regulator of the circadian clock that interacts with the CLOCK:BMAL1 complex to repress its transcriptional activation. This suggests that PASD1 may contribute to oncogenic transformation through the suppression of circadian rhythms.
Conjugation: Unconjugated
Isotype: IgG
Molecular weight: 100 kDa
Immunogen: GST-PASD1 recombinant protein containing 195-474 aas of PASD1. Region is common to PASD1a and PASD1b proteins.
Myeloma used: NS0
Target background: Cancer testis antigens (CTAs) such as PASD1 represent attractive immunotherapy targets, having normal tissue expression that is testis restricted and commonly widespread expression in tumours. PASD1 was originally identified as a target of anti-tumour immune responses in patients with aggressive diffuse large B-cell lymphoma. Subsequent studies have identified PASD1 expression in myeloma patients (both pre- and post-treatment) and in a broad range of solid tumours, 65/160 samples (41%) from 9 histological types. Interestingly a new immune response to PASD1 was detected in a melanoma patient who exhibited a systemic immune response to palliative radiotherapy with regression of nonirradiated lesions, the abscopal effect. Delivery of immunogenic PASD1 peptides using a DNA vaccine was able to induce immune responses in preclinical models, demonstrating its potential for immunotherapy applications. There is relatively little information regarding the function of many CTAs. However, recently PASD1 has been identified as a novel regulator of the circadian clock that interacts with the CLOCK:BMAL1 complex to repress its transcriptional activation. This suggests that PASD1 may contribute to oncogenic transformation through the suppression of circadian rhythms.
Format: Liquid
Concentration: 0.9-1.1 mg/ml
Storage buffer: PBS with 0.02% azide
Storage conditions: -20° C
Shipping conditions: Dry ice
References:

Boullosa et al. 2018. Oncotarget. 9(3):3853-3866. PMID: 29423088.

Identification of survivin as a promising target for the immunotherapy of adult B-cell acute lymphoblastic leukemia.

Brooks et al. 2015. PLoS One. 10(10):e0140483. PMID: 26492414.

Application of the pMHC Array to Characterise Tumour Antigen Specific T Cell Populations in Leukaemia Patients at Disease Diagnosis.

Khan et al. 2015. Biomark Cancer. 7:31-8. PMID: 26327782.

Infrequent Expression of the Cancer-Testis Antigen, PASD1, in Ovarian Cancer.

Michael et al. 2015. Mol Cell. 58(5):743-54. PMID: 25936801.

Cancer/Testis Antigen PASD1 Silences the Circadian Clock.

Hardwick et al. 2013. Cancer Immun. 13:16. PMID: 23882161.

An analogue peptide from the Cancer/Testis antigen PASD1 induces CD8+ T cell responses against naturally processed peptide.

Ait-Tahar et al. 2011. Haematologica. 96(1):78-86. PMID: 20851862.

Joseph-Pietras et al. 2010. Leukemia. 24(11):1951-9. PMID: 20861911.

DNA vaccines to target the cancer testis antigen PASD1 in human multiple myeloma.

CD4-positive T-helper cell responses to the PASD1 protein in patients with diffuse large B-cell lymphoma.

Ait-Tahar et al. 2009. Br J Haematol. 146(4):396-407. PMID: 19552722.

Cytolytic T-cell response to the PASD1 cancer testis antigen in patients with diffuse large B-cell lymphoma.

Cooper et al. 2006. Leukemia. 20(12):2172-4. PMID: 17024112.

Sahota et al. 2006. Blood. 108(12):3953-5. PMID: 17114574.

PASD1 is a potential multiple myeloma-associated antigen.

PASD1, a DLBCL-associated cancer testis antigen and candidate for lymphoma immunotherapy.

Related Tools for Antibodies

Cat. # Tool Name
151015 Anti-CyclinA [E70.1] Key Info View Tool
151021 Anti-CyclinB1 [V152] Key Info View Tool
151027 Anti-HSVICP8 [10A3] Key Info View Tool
151034 Anti-HSVUL42 [13D11] Key Info View Tool
151037 Anti-Cdk1 [17 (A17)] Key Info View Tool

Tool enquiry

Please ensure you use your organisation email address rather than personal where possible, as this helps us locate your organisation in our system faster.

Please note we may take up to three days to respond to your enquiry.

CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.